Workflow
2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy
BEAMBeam Therapeutics(BEAM) Schaeffers Investment Research·2025-01-10 16:30

Beam Therapeutics (BEAM) - The company is developing a pipeline using base editing technology, which modifies single DNA or RNA bases without cutting the DNA strand [1] - Beam Therapeutics ended Q2 with 1billionincash,providinganoperatingrunwayinto2027[1]−Thecompanyrecentlyreceivednewdrugclearanceforitsfirstin−vivoregulatoryfiling,enablinggeneticmodificationsviananoparticlesinjectedintothebody[2]−InitialclinicaldataforBEAM−302inAlpha−1AntitrypsinDeficiency(AATD)isexpectedin2025,withthefirstpatientdosedinphase1and2trials[3]−NewplayersinthebiotechspacecouldlicenseBeam′sbase−editingtechnology,potentiallybenefitingthecompanyanditsshares[3]BloomEnergy(BE)−BloomEnergysignedanagreementwithAmericanElectricPower(AEP)inNovembertoprovidepowersolutionstodatacenters[4]−Thestockhaspulledbacktoits501 billion in cash, providing an operating runway into 2027 [1] - The company recently received new drug clearance for its first in-vivo regulatory filing, enabling genetic modifications via nanoparticles injected into the body [2] - Initial clinical data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) is expected in 2025, with the first patient dosed in phase 1 and 2 trials [3] - New players in the biotech space could license Beam's base-editing technology, potentially benefiting the company and its shares [3] Bloom Energy (BE) - Bloom Energy signed an agreement with American Electric Power (AEP) in November to provide power solutions to data centers [4] - The stock has pulled back to its 50% year-to-date level, aligning with its 5 billion valuation and technical support levels [4] - A potential upward movement in the stock could occur in 2025, supported by technical indicators [4] - Bloom Energy is considered a contrarian target with relative strength leadership and significant skepticism among investors [5] - Short interest in BE has reached all-time highs, increasing by 16% in the last 30 days and 48% in 2024, with 23% of the equity's total available float sold short, indicating potential for a short squeeze [5]